Onyx Biotec Open Offer
VC Corporate Advisors filed a corrigendum to Onyx Biotec's open offer letter of offer. The offer seeks up to 47,14,372 shares, or 26% of paid-up capital.
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
18 announcements with these filters
VC Corporate Advisors filed a corrigendum to Onyx Biotec's open offer letter of offer. The offer seeks up to 47,14,372 shares, or 26% of paid-up capital.
Onyx Biotec Limited has submitted the quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018, for the quarter ended September 30, 2026.
Onyx Biotec's Committee of Independent Directors met to review the open offer by the identified acquirers to purchase 26% of the company's equity share capital.
Bhardwaj acquirers launch a ₹172.07 Crore open offer for 26% of Onyx Biotec at ₹36.5 per share. Tendering runs October 13–27, 2026.
Onyx Biotec Limited held its 21st Annual General Meeting on September 28, 2026. The meeting covered standard agenda items including financial statement adoption and director appointments.
Onyx Biotec Limited will hold its 21st Annual General Meeting on September 28, 2026, via video conferencing to transact the company's business.
Onyx Biotec Limited has announced a change in the designation of Mr. Naresh Kumar from Whole-Time Director to Executive Director, effective September 3, 2026.
Onyx Biotec Ltd. announced its board meeting outcomes, including the 21st AGM convening, cost auditor appointment, and a director's designation change to Managing Director.
VC Corporate Advisors has filed a Detailed Public Statement for an open offer to acquire 26% stake in Onyx Biotec Limited at ₹36.50 per share.
Onyx Biotec Ltd states corporate‑governance rules do not apply as it is listed on NSE EMERGE and meets small‑cap criteria. The filing complies with SEBI Regulation 15.
Promoters Sanjay Jain and Fateh Pal Singh disposed of equity shares. Sanjay Jain sold shares valued at ₹3.41 Crore via the open market.
Promoter Fateh Pal Singh disclosed the sale of 124,000 (0.68%) equity shares of Onyx Biotec Ltd on the NSE. The disposal is recorded under SEBI Regulation 7.
Onyx Biotec clarified that recent share price volatility is purely market-driven with no undisclosed material information. The company reiterated its commitment to SEBI listing compliance.
Promoter Sanjay Jain sold 17,74,000 shares of Onyx Biotec Limited for ₹5.44 Crore via the open market. This transaction reduced his equity stake from 21.48% to 11.70%.
Managing Director Sanjay Jain and Whole Time Director Lakshya Jain resigned from Onyx Biotec Ltd. Their departures are effective May 27, 2026, citing personal reasons.
Onyx Biotec Limited confirmed zero deviation in utilizing ₹25.38 Crore raised through its IPO. Funds were deployed for manufacturing upgrades, loan repayments, and general corporate purposes.
Onyx Biotec Ltd reported revenue from operations of ₹34.9 Cr (+9.7% YoY) and net profit of ₹0.7 Cr (-65.0% YoY) for H2 FY26.
Onyx Biotec Limited approved audited financial results for the year ended March 31, 2026. The company reported utilization of ₹25.38 Crore from its recent IPO proceeds.